Kymera Therapeutics, Inc. (KYMR): who owns it and who trades it
As of Nov 16, 2026, KYMR insiders reported 270 open-market sales worth $473M and 2 purchases worth $172M in the last 12 months, with 44% of the sale value made under pre-set 10b5-1 plans. The largest seller was Bruce Booth (Director), with $226M. 2 of the 50 famous funds we follow held it at their last quarter end.
Latest filing Nov 16, 2026. From Form 4, 13F and Schedule 13D/G filings.
At a glance
Who is buying and selling Kymera Therapeutics
From the latest filingsOverall: about as much buying as selling. Insiders mostly sold. Famous investors mostly bought. Funds was close to even.
Each group counts equally in the meter, by the number of buyers and sellers, not dollars. Insider sales under pre-set 10b5-1 plans are left out of it. From SEC, House and Senate filings; not advice.
Who owns KYMR
274 funds and institutions reported KYMR shares worth $11.1B at the end of Q2 2026. Some shares are counted by more than one filer, or lent out and counted twice, so the total can pass 100%. The largest holder is FMR LLC (Fidelity) with 15.0%.
Funds and institutions (13F) about 100%Everyone else 0%
10 largest owners, by share of the company
Top 20 owners
| Owner | Shares | % of company | Value | Change since Q1 2026 |
|---|---|---|---|---|
| FMR LLC (Fidelity) | 12.35M | 15.01% | $1.4B | +6% |
| Baker Bros. Advisors LP | 8.66M | 10.52% | $993M | No change |
| Avoro Capital Advisors LLC | 7.47M | 9.09% | $857M | No change |
| T. Rowe Price Associates | 7.11M | 8.65% | $816M | +17% |
| T. Rowe Price Investment Management, Inc. | 6.26M | 7.61% | $718M | +14% |
| BlackRock, Inc. | 5.54M | 6.73% | $635M | +9% |
| Bvf Inc | 3.87M | 4.71% | $444M | -30% |
| Wellington Management Group LLP | 3.68M | 4.47% | $421M | -6% |
| Vanguard Portfolio Management LLC | 2.99M | 3.64% | $343M | +4% |
| Siren, L.L.C. | 2.94M | 3.57% | $337M | -8% |
| Vanguard Capital Management LLC | 2.93M | 3.56% | $336M | +2% |
| Atlas Venture Life Science Advisors, LLC | 2.85M | 3.46% | $327M | -38% |
| State Street Corp | 2.74M | 3.33% | $314M | +15% |
| Geode Capital Management, LLC | 1.82M | 2.21% | $208M | +10% |
| Capital Research Global Investors | 1.39M | 1.69% | $159M | -17% |
| Goldman Sachs Group Inc | 1.19M | 1.44% | $136M | +34% |
| UBS Group AG | 1.01M | 1.23% | $116M | -2% |
| Alliancebernstein L.P. | 981,521 | 1.19% | $81.8M | +11% |
| Driehaus Capital Management LLC | 919,233 | 1.12% | $105M | -12% |
| Merck & Co., Inc. | 772,165 | 0.94% | $88.5M | No change |
From the SEC 13F data sets: every fund manager with over $100M must report its US stock holdings every 3 months, up to 45 days after the quarter ends. Owners are shown as they file, so one group (for example Vanguard) can appear under several names. Individuals, most insiders and smaller funds do not file 13F reports.
Insider trades
In the last 12 months, KYMR insiders reported $172M of open-market purchases and $473M of sales. 44% of the sale value was under a 10b5-1 plan, a schedule set up in advance.
Purchases and sales by month
Latest trades
| Date | Insider | Role | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|---|
| Oct 1, 2026 | Nello Mainolfi | CEO | Sale plan | 3,525 | $111.44 | $393K | Form 4 |
| Oct 1, 2026 | Nello Mainolfi | CEO | Sale plan | 5,506 | $112.42 | $619K | Form 4 |
| Oct 1, 2026 | Nello Mainolfi | CEO | Sale plan | 4,876 | $113.24 | $552K | Form 4 |
| Oct 1, 2026 | Nello Mainolfi | CEO | Sale plan | 7,601 | $114.43 | $870K | Form 4 |
| Oct 1, 2026 | Nello Mainolfi | CEO | Sale plan | 8,230 | $115.40 | $950K | Form 4 |
| Oct 1, 2026 | Nello Mainolfi | CEO | Sale plan | 262 | $116.12 | $30.4K | Form 4 |
| Sep 4, 2026 | Brian Adams | Chief Legal Officer | Sale | 1,209 | $115.55 | $140K | Form 4 |
| Sep 4, 2026 | Brian Adams | Chief Legal Officer | Sale | 3,025 | $116.81 | $353K | Form 4 |
| Sep 4, 2026 | Brian Adams | Chief Legal Officer | Sale | 2,137 | $117.57 | $251K | Form 4 |
| Jul 7, 2026 | Nello Mainolfi | CEO | Sale | 50,000 | $119.00 | $6M | Form 4 |
| Jul 1, 2026 | Noah Goodman | Chief Business Officer | Sale | 3,389 | $114.29 | $387K | Form 4 |
| Jul 1, 2026 | Nello Mainolfi | CEO | Sale | 1,883 | $112.80 | $212K | Form 4 |
| Jul 1, 2026 | Nello Mainolfi | CEO | Sale | 6,626 | $113.98 | $755K | Form 4 |
| Jul 1, 2026 | Nello Mainolfi | CEO | Sale | 44,050 | $115.69 | $5.1M | Form 4 |
| Jul 1, 2026 | Nello Mainolfi | CEO | Sale | 24,105 | $114.96 | $2.8M | Form 4 |
| Jul 1, 2026 | Nello Mainolfi | CEO | Sale | 3,336 | $116.56 | $389K | Form 4 |
| Jun 30, 2026 | Bruce N. Jacobs | CFO | Sale | 1,100 | $112.79 | $124K | Form 4 |
| Jun 30, 2026 | Bruce N. Jacobs | CFO | Sale | 4,110 | $114.19 | $469K | Form 4 |
| Jun 30, 2026 | Bruce N. Jacobs | CFO | Sale | 51,375 | $114.77 | $5.9M | Form 4 |
| Jun 30, 2026 | Bruce N. Jacobs | CFO | Sale | 1,700 | $111.57 | $190K | Form 4 |
| Jun 30, 2026 | Bruce N. Jacobs | CFO | Sale | 1,500 | $110.54 | $166K | Form 4 |
| Jun 30, 2026 | Bruce N. Jacobs | CFO | Sale | 7,971 | $115.82 | $923K | Form 4 |
| Jun 30, 2026 | Bruce N. Jacobs | CFO | Sale | 3,200 | $117.70 | $377K | Form 4 |
| Jun 30, 2026 | Bruce N. Jacobs | CFO | Sale | 6,153 | $116.99 | $720K | Form 4 |
| Jun 29, 2026 | Bruce Booth | Director | Sale plan | 10,848 | $108.28 | $1.2M | Form 4 |
| Jun 29, 2026 | Bruce Booth | Director | Sale plan | 7,968 | $109.75 | $874K | Form 4 |
| Jun 29, 2026 | Bruce Booth | Director | Sale plan | 7,723 | $110.67 | $855K | Form 4 |
| Jun 29, 2026 | Bruce Booth | Director | Sale plan | 770 | $105.78 | $81.5K | Form 4 |
| Jun 29, 2026 | Bruce Booth | Director | Sale plan | 2,133 | $106.63 | $227K | Form 4 |
| Jun 29, 2026 | Bruce Booth | Director | Sale plan | 2,698 | $107.76 | $291K | Form 4 |
| Jun 29, 2026 | Bruce Booth | Director | Sale plan | 1,498 | $108.28 | $162K | Form 4 |
| Jun 29, 2026 | Bruce Booth | Director | Sale plan | 1,104 | $109.75 | $121K | Form 4 |
| Jun 29, 2026 | Bruce Booth | Director | Sale plan | 1,078 | $110.67 | $119K | Form 4 |
| Jun 29, 2026 | Bruce Booth | Director | Sale plan | 130 | $111.20 | $14.5K | Form 4 |
| Jun 29, 2026 | Bruce Booth | Director | Sale plan | 19,419 | $107.76 | $2.1M | Form 4 |
| Jun 29, 2026 | Bruce Booth | Director | Sale plan | 14,798 | $106.63 | $1.6M | Form 4 |
| Jun 29, 2026 | Bruce Booth | Director | Sale plan | 5,549 | $105.78 | $587K | Form 4 |
| Jun 29, 2026 | Bruce Booth | Director | Sale plan | 934 | $111.20 | $104K | Form 4 |
| Jun 29, 2026 | Bruce Booth | Director | Sale plan | 10,658 | $108.28 | $1.2M | Form 4 |
| Jun 29, 2026 | Bruce Booth | Director | Sale plan | 7,833 | $109.75 | $860K | Form 4 |
| Jun 29, 2026 | Bruce Booth | Director | Sale plan | 157 | $111.20 | $17.5K | Form 4 |
| Jun 29, 2026 | Bruce Booth | Director | Sale plan | 1,199 | $110.67 | $133K | Form 4 |
| Jun 29, 2026 | Bruce Booth | Director | Sale plan | 7,602 | $110.67 | $841K | Form 4 |
| Jun 29, 2026 | Bruce Booth | Director | Sale plan | 907 | $111.20 | $101K | Form 4 |
| Jun 29, 2026 | Bruce Booth | Director | Sale plan | 1,688 | $108.28 | $183K | Form 4 |
| Jun 29, 2026 | Bruce Booth | Director | Sale plan | 1,239 | $109.75 | $136K | Form 4 |
| Jun 29, 2026 | Bruce Booth | Director | Sale plan | 5,471 | $105.78 | $579K | Form 4 |
| Jun 29, 2026 | Bruce Booth | Director | Sale plan | 14,613 | $106.63 | $1.6M | Form 4 |
| Jun 29, 2026 | Bruce Booth | Director | Sale plan | 19,093 | $107.76 | $2.1M | Form 4 |
| Jun 29, 2026 | Bruce Booth | Director | Sale plan | 848 | $105.78 | $89.7K | Form 4 |
| Jun 29, 2026 | Bruce Booth | Director | Sale plan | 2,318 | $106.63 | $247K | Form 4 |
| Jun 29, 2026 | Bruce Booth | Director | Sale plan | 3,024 | $107.76 | $326K | Form 4 |
| Jun 26, 2026 | Bruce Booth | Director | Sale plan | 28,296 | $107.57 | $3M | Form 4 |
| Jun 26, 2026 | Bruce Booth | Director | Sale plan | 231,007 | $108.14 | $25M | Form 4 |
| Jun 26, 2026 | Bruce Booth | Director | Sale plan | 32,624 | $109.79 | $3.6M | Form 4 |
| Jun 26, 2026 | Bruce Booth | Director | Sale plan | 11,277 | $110.49 | $1.2M | Form 4 |
| Jun 26, 2026 | Bruce Booth | Director | Sale plan | 10,366 | $111.51 | $1.2M | Form 4 |
| Jun 26, 2026 | Bruce Booth | Director | Sale plan | 555 | $112.49 | $62.4K | Form 4 |
| Jun 26, 2026 | Bruce Booth | Director | Sale plan | 14,913 | $113.97 | $1.7M | Form 4 |
| Jun 26, 2026 | Bruce Booth | Director | Sale plan | 27,951 | $114.94 | $3.2M | Form 4 |
| Jun 26, 2026 | Bruce Booth | Director | Sale plan | 6,821 | $115.69 | $789K | Form 4 |
| Jun 26, 2026 | Bruce Booth | Director | Sale plan | 12,181 | $117.09 | $1.4M | Form 4 |
| Jun 26, 2026 | Bruce Booth | Director | Sale plan | 22,046 | $117.85 | $2.6M | Form 4 |
| Jun 26, 2026 | Bruce Booth | Director | Sale plan | 12,390 | $118.66 | $1.5M | Form 4 |
| Jun 26, 2026 | Bruce Booth | Director | Sale plan | 3,958 | $107.57 | $426K | Form 4 |
| Jun 26, 2026 | Bruce Booth | Director | Sale plan | 32,402 | $108.14 | $3.5M | Form 4 |
| Jun 26, 2026 | Bruce Booth | Director | Sale plan | 4,562 | $109.79 | $501K | Form 4 |
| Jun 26, 2026 | Bruce Booth | Director | Sale plan | 1,579 | $110.49 | $174K | Form 4 |
| Jun 26, 2026 | Bruce Booth | Director | Sale plan | 1,442 | $111.51 | $161K | Form 4 |
| Jun 26, 2026 | Bruce Booth | Director | Sale plan | 78 | $112.49 | $8.8K | Form 4 |
| Jun 26, 2026 | Bruce Booth | Director | Sale plan | 2,083 | $113.97 | $237K | Form 4 |
| Jun 26, 2026 | Bruce Booth | Director | Sale plan | 3,896 | $114.94 | $448K | Form 4 |
| Jun 26, 2026 | Bruce Booth | Director | Sale plan | 952 | $115.69 | $110K | Form 4 |
| Jun 26, 2026 | Bruce Booth | Director | Sale plan | 1,701 | $117.09 | $199K | Form 4 |
| Jun 26, 2026 | Bruce Booth | Director | Sale plan | 3,069 | $117.85 | $362K | Form 4 |
| Jun 26, 2026 | Bruce Booth | Director | Sale plan | 1,729 | $118.66 | $205K | Form 4 |
| Jun 26, 2026 | Biotechnology Value Fund Ii Lp +9 | Director | Sale | 837,914 | $106.50 | $89.2M | Form 4 |
| Jun 26, 2026 | Biotechnology Value Fund Ii Lp +9 | Director | Sale | 51,858 | $106.50 | $5.5M | Form 4 |
| Jun 26, 2026 | Biotechnology Value Fund Ii Lp +9 | Director | Sale | 113,289 | $106.50 | $12.1M | Form 4 |
| Jun 26, 2026 | Biotechnology Value Fund Ii Lp +9 | Director | Sale | 627,597 | $106.50 | $66.8M | Form 4 |
| Jun 25, 2026 | Bruce Booth | Director | Sale plan | 305 | $128.69 | $39.3K | Form 4 |
| Jun 25, 2026 | Bruce Booth | Director | Sale plan | 46 | $129.61 | $6K | Form 4 |
| Jun 25, 2026 | Bruce Booth | Director | Sale plan | 37,179 | $119.71 | $4.5M | Form 4 |
| Jun 25, 2026 | Bruce Booth | Director | Sale plan | 112,299 | $120.66 | $13.5M | Form 4 |
| Jun 25, 2026 | Bruce Booth | Director | Sale plan | 40,774 | $121.38 | $4.9M | Form 4 |
| Jun 25, 2026 | Bruce Booth | Director | Sale plan | 4,977 | $122.67 | $611K | Form 4 |
| Jun 25, 2026 | Bruce Booth | Director | Sale plan | 10,860 | $123.62 | $1.3M | Form 4 |
| Jun 25, 2026 | Bruce Booth | Director | Sale plan | 11,711 | $124.61 | $1.5M | Form 4 |
| Jun 25, 2026 | Bruce Booth | Director | Sale plan | 3,716 | $125.82 | $468K | Form 4 |
| Jun 25, 2026 | Bruce Booth | Director | Sale plan | 1,609 | $126.71 | $204K | Form 4 |
| Jun 25, 2026 | Bruce Booth | Director | Sale plan | 25,075 | $127.37 | $3.2M | Form 4 |
| Jun 25, 2026 | Bruce Booth | Director | Sale plan | 2,197 | $128.69 | $283K | Form 4 |
| Jun 25, 2026 | Bruce Booth | Director | Sale plan | 337 | $129.61 | $43.7K | Form 4 |
| Jun 25, 2026 | Bruce Booth | Director | Sale plan | 5,144 | $119.71 | $616K | Form 4 |
| Jun 25, 2026 | Bruce Booth | Director | Sale plan | 15,660 | $120.66 | $1.9M | Form 4 |
| Jun 25, 2026 | Bruce Booth | Director | Sale plan | 5,689 | $121.38 | $691K | Form 4 |
| Jun 25, 2026 | Bruce Booth | Director | Sale plan | 698 | $122.67 | $85.6K | Form 4 |
| Jun 25, 2026 | Bruce Booth | Director | Sale plan | 1,517 | $123.62 | $188K | Form 4 |
| Jun 25, 2026 | Bruce Booth | Director | Sale plan | 1,639 | $124.61 | $204K | Form 4 |
| Jun 25, 2026 | Bruce Booth | Director | Sale plan | 522 | $125.82 | $65.7K | Form 4 |
Latest 100 of 272 trades in the last 12 months.
Insiders by value traded
| Insider | Role | Bought | Sold | Last trade |
|---|---|---|---|---|
| Bruce Booth | Director | – | $226M | Jun 29, 2026 |
| Biotechnology Value Fund Ii Lp | Director | – | $174M | Jun 26, 2026 |
| Felix Baker | Director, 10% owner | $172M | – | Dec 11, 2025 |
| Nello Mainolfi | Chief Executive Officer, Director | – | $35M | Oct 1, 2026 |
| Jeremy G Chadwick | Chief Operating Officer | – | $15.6M | May 27, 2026 |
| Bruce N. Jacobs | Chief Financial Officer | – | $9.5M | Jun 30, 2026 |
| Jared Gollob | Chief Medical Officer | – | $5.3M | Mar 4, 2026 |
| Pamela Esposito | Director | – | $3.1M | Mar 20, 2026 |
| Noah Goodman | Chief Business Officer | – | $2.2M | Jul 1, 2026 |
| Elena Ridloff | Director | – | $1.3M | May 11, 2026 |
| Brian Adams | Chief Legal Officer | – | $744K | Sep 4, 2026 |
| Jeffrey W. Albers | Director | – | $449K | Dec 8, 2025 |
What this data shows, and what it doesn't
- Shows: open-market purchases and sales by officers, directors and 10%+ owners, reported on Form 4 within two business days of the trade.
- Leaves out: stock awards, option exercises, shares withheld for tax and gifts. These are not trades at a market price chosen by the insider.
- "plan" marks a sale made under a Rule 10b5-1 plan, a schedule set up in advance.
- Fund holders come from 13F reports, a snapshot at quarter end filed up to 45 days later.
- Filings are self-reported and can be amended. Each trade links to its original filing. Methodology
KYMR short interest
Moderate short interest. 9.8% of KYMR shares are sold short: about 1 share in 10. Over the last 12 reports the number of shares short went down 16%.
As a rough guide, under 5% is low, 5–10% is moderate, 10–20% is high and over 20% is very high.
As of Oct 30, 2026, 8.40M KYMR shares were sold short, 9.8% of the shares outstanding, down 8.4% from the report before. At the average daily volume of 800,703 shares, buying them all back would take about 10.5 trading days (days to cover).
Shares short, % of all shares
Days to cover
Every report
| Settlement date | Shares short | % of shares | Change | Avg daily volume | Days to cover |
|---|---|---|---|---|---|
| Oct 30, 2026 | 8.40M | 9.84% | -8% | 800,703 | 10.5 |
| Oct 15, 2026 | 9.17M | 11.03% | -7% | 920,938 | 10.0 |
| Sep 30, 2026 | 9.91M | 11.92% | -6% | 828,028 | 12.0 |
| Sep 15, 2026 | 10.53M | 12.66% | +2% | 652,859 | 16.1 |
| Aug 31, 2026 | 10.37M | 12.47% | -0% | 616,319 | 16.8 |
| Aug 14, 2026 | 10.38M | 12.49% | +4% | 744,554 | 13.9 |
| Jul 31, 2026 | 9.98M | 12.00% | +1% | 552,036 | 18.1 |
| Jul 15, 2026 | 9.90M | 12.04% | -2% | 674,870 | 14.7 |
| Jun 30, 2026 | 10.15M | 12.33% | +2% | 1.92M | 5.3 |
| Jun 15, 2026 | 9.96M | 12.11% | -1% | 639,045 | 15.6 |
| May 29, 2026 | 10.10M | 12.28% | +1% | 490,785 | 20.6 |
| May 15, 2026 | 10.00M | 12.16% | +3% | 469,885 | 21.3 |
Short sellers borrow shares and sell them, hoping to buy them back for less. A high number means many such bets are open. It does not say where the price will go. Source: FINRA equity short interest, reported by brokers twice a month (positions on the 15th and the last business day) and published about 7 business days later. % of shares uses the share count on the company's latest SEC filing. What short interest means · Most shorted stocks
Kymera Therapeutics company events
Kymera Therapeutics filed 14 reports on Form 8-K in the last 12 months, 2 of them about an important change (leadership). The latest was on Oct 29, 2026.
- Oct 29, 2026ResultsReleased financial results. Filing
- Aug 5, 2026ResultsReleased financial results. Filing
- Jul 27, 2026LeadershipJared Gollob, M.D., communicated his intention to retire from his role as Chief Medical Officer of Kymera Therapeutics, Inc. and submitted his resignation on July 27, 2026. Filing
- Jun 25, 2026AnnouncementThe Company announced that it has completed enrollment in the global BROADEN2 Phase 2b trial of KT-621, its first-in-class, oral STAT6 degrader, for the treatment of moderate to severe atopic dermatitis. Filing
- Jun 24, 2026VoteReported shareholder vote results. Filing
- Jun 8, 2026LeadershipJeremy Chadwick communicated his intention to retire and submitted his resignation as Chief Operating Officer on June 5, 2026. Filing
- Apr 30, 2026ResultsReleased financial results. Filing
- Mar 27, 2026RulesChanged its bylaws or articles. Filing
- Feb 26, 2026AgreementKymera Therapeutics, Inc. entered into a Sales Agreement, with TD Securities (USA) LLC with respect to an “at-the-market” offering program under which the Company may issue and sell, from time to time at the Company’s sole discretion, shares of the Company’s common stock, having an aggregate… Filing
- Feb 26, 2026ResultsReleased financial results. Filing
- Jan 13, 2026ResultsReleased financial results. Filing
- Dec 10, 2025AgreementKymera Therapeutics, Inc. entered into an underwriting agreement with Morgan Stanley & Co. LLC, J.P. Morgan Securities LLC, Jefferies LLC, Stifel, Nicolaus & Company, Incorporated, Guggenheim Securities, LLC and Wells Fargo Securities, LLC, as representatives of the underwriters listed in Schedule… Filing
- Dec 8, 2025AnnouncementShared information with investors. Filing
- Dec 8, 2025AnnouncementThe Company announced the results from the Company’s BroADen Phase 1b AD patient clinical trial of KT-621, its first-in-class, oral STAT6 degrader medicine. Filing
From 8-K reports, which a company must file within 4 business days of an important event. Where a report is about a change such as a new CEO, the sentence is the first one from the report itself, shortened. Each row links to the original filing. Company events this week
Kymera Therapeutics financials
Famous investors that hold KYMR
2 of the 50 well-known investors we track reported holding KYMR in their latest 13F filing. The largest position is Ken Fisher's, worth $36.1M.
| Fund | Quarter | Shares | Value | Of portfolio | Change |
|---|---|---|---|---|---|
| Ken Fisher · Fisher Asset Management | Q3 2026 | 323,219 | $36.1M | 0.0% | +2439% |
| Steve Cohen · Point72 Asset Management | Q3 2026 | 211,218 | $23.6M | 0.0% | New |
From 13F reports: a snapshot at quarter end, filed up to 45 days later. Change compares with the quarter before.
5%+ stakes filed in the last 120 days
Anyone who owns more than 5% of a company must report it on Schedule 13D or 13G. 2 filings named KYMR in the last 120 days.
| Filed | Holder | Form | Stake |
|---|---|---|---|
| Oct 27, 2026 | BlackRock, Inc. | 13G/A | 6.6% |
| Oct 27, 2026 | BlackRock, Inc. | 13G/A | 6.6% |
Questions about Kymera Therapeutics, Inc. (KYMR) stock
Who owns the most KYMR stock?
The largest reported owner of Kymera Therapeutics, Inc. (KYMR) is FMR LLC (Fidelity), with 15.0% of the company. In total, 274 funds and institutions reported holding KYMR at the end of Q2 2026, together about 100% of the shares. See the largest owners.
Are KYMR insiders buying or selling?
In the last 12 months, KYMR insiders reported 2 open-market purchases worth $172M and 270 sales worth $473M. The latest trade was on Oct 1, 2026. See every trade.
What is the short interest in KYMR?
As of Oct 30, 2026, 8.40M KYMR shares were sold short, 9.8% of the shares outstanding, down 8.4% from the report before. At the average daily volume of 800,703 shares, buying them all back would take about 10.5 trading days (days to cover). See the history.
Which famous investors hold KYMR?
2 of the 50 well-known investors we track reported KYMR in their latest 13F filing, including Ken Fisher, Steve Cohen. The largest position is worth $36.1M. See all holders.
Executive pay
Kymera Therapeutics's chief executive was paid a total of $8.5M for the year ended Dec 31, 2025, down 45% from $15.4M the year before. In the last 12 months, Kymera Therapeutics's executives and directors bought $172M of stock on the open market and sold $299M.
From the pay versus performance table in the company's annual proxy statement (DEF 14A), as the company reported it. If the chief executive changed during the year, the company reports each person separately and this shows one of them.
Source: SEC Form 4 (insiders, filed within 2 business days), 13F (funds, up to 45 days after quarter end) and Schedule 13D/13G filings. Only open-market purchases (code P) and sales (code S) are shown. Data only, not investment advice. How we collect it.